Ameriprise’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Ameriprise’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,000	Closed	-$2.92K	–	4002
2023 Q4	$2.92K	Hold	15,000	–	–	﹤0.01%	3890
2023 Q3	$5.49K	Hold	15,000	–	–	﹤0.01%	3880
2023 Q2	$16.2K	Hold	15,000	–	–	﹤0.01%	3885
2023 Q1	$10.5K	Hold	15,000	–	–	﹤0.01%	3914
2022 Q4	$17K	Hold	15,000	–	–	﹤0.01%	3902
2022 Q3	$26K	Buy	+15,000	New	+$27.4K	﹤0.01%	3916

Other funds holding BTTX

CIAS

Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Ameriprise's BTTX Position: Q1 2024 in Review

Ameriprise sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 15,000 shares — an estimated $2.92K sold.

Ameriprise first reported a position in BTTX in Q3 2022 and held it in 6 quarters. The position peaked at $26K in Q3 2022. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

Ameriprise reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Ameriprise sold 15,000 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.92K.
Ameriprise first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
Ameriprise's Better Therapeutics, Inc. Common Stock position peaked at $26K in Q3 2022.
3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.